Skip to main content
Equibles

BANK OF AMERICA CORP /DE/

Bank

Position in VRTX — Vertex Pharmaceuticals Inc / Ma

CIK 70858 CHARLOTTE, NC
Back to VRTX Full portfolio

Position in VRTX

as of Mar 31, 2026 · filed May 18, 2026
Position Value
$1,285,223,834
-$46,308,084 QoQ
Shares Held
2,878,183
-2.0% QoQ
Ownership
1.13%
of shares outstanding
% of Portfolio
0.16%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 24.832159734110025.ToString("F0")% Shared 0.ToString("F0")% None 75.16784026588998.ToString("F0")%

Common Shares in VRTX Over Time

Shares Held

Position Value (USD)

Derivatives in VRTX

reported options exposure · as of Sep 30, 2025
CallValue
$18,994,540
CallShares
48,500
PutValue
$25,495,764
PutShares
65,100

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

BANK OF AMERICA CORP /DE/ holds $8,554,846,017 across 346 Biotechnology names. VRTX ranks #1 (15.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
This page 		2,878,183 $1,285,223,834
2 REGN
Regeneron Pharmaceuticals, Inc.
 1,189,584 $919,120,177
3 ALNY
Alnylam Pharmaceuticals, Inc.
 966,912 $319,922,169
4 ARGX
Argenx SE
 400,117 $292,185,437
5 INSM
INSMED Inc
 1,502,281 $245,652,986
6 CYTK
Cytokinetics Inc
 3,125,436 $205,997,485
7 JAZZ
Jazz Pharmaceuticals plc
 1,014,800 $191,847,936
8 HALO
Halozyme Therapeutics, Inc.
 2,913,109 $188,274,232

All Filings in VRTX

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $1,285,223,834 2,878,183
2025-12-31 $1,331,531,918 2,937,030
2025-09-30 $25,495,764 65,100
2025-09-30 $18,994,540 48,500
2025-09-30 $1,112,423,651 2,840,424
2025-06-30 $1,113,000 2,500
2025-06-30 $10,239,600 23,000
2025-06-30 $1,249,951,086 2,807,617
2025-03-31 $2,618,028 5,400
2025-03-31 $1,389,008,326 2,864,998
2025-03-31 $10,278,184 21,200
2024-12-31 $974,273,449 2,419,353
2024-12-31 $4,027,000 10,000
2024-12-31 $4,228,350 10,500
2024-09-30 $1,213,373,717 2,608,957
2024-09-30 $9,441,124 20,300
2024-09-30 $4,836,832 10,400
2024-06-30 $1,205,775,165 2,572,485
2024-06-30 $4,874,688 10,400
2024-06-30 $11,483,640 24,500
2024-03-31 $16,469,594 39,400
2024-03-31 $1,063,684,128 2,544,638
2024-03-31 $40,588,771 97,100
2023-12-31 $43,496,541 106,900
2023-12-31 $991,151,486 2,435,920
2023-12-31 $48,257,154 118,600
2023-09-30 $15,856,944 45,600
2023-09-30 $818,232,564 2,353,001
2023-09-30 $13,422,764 38,600
2023-06-30 $25,443,093 72,300
2023-06-30 $823,495,789 2,340,075
2023-06-30 $23,577,970 67,000
2023-03-31 $18,683,651 59,300
2023-03-31 $814,501,317 2,585,144
2023-03-31 $15,249,388 48,400
2022-12-31 $721,100,983 2,497,060
2022-12-31 $15,709,632 54,400
2022-12-31 $12,533,052 43,400
2022-09-30 $11,176,244 38,600
2022-09-30 $731,799,317 2,527,455
2022-09-30 $9,728,544 33,600
2022-06-30 $759,930,705 2,696,798
2022-06-30 $4,283,208 15,200
2022-03-31 $1,748,499 6,700
2022-03-31 $7,620,324 29,200
2022-03-31 $813,847,207 3,118,547
2021-12-31 $680,324,530 3,098,017
2021-12-31 $307,440 1,400
2021-12-31 $483,120 2,200
2021-09-30 $18,048,305 99,500

Report a Problem

Category
Description
Email (optional, for follow-up)